文献速递肝病

HBsAg低于100 IU/mL患者停用恩替卡韦或替诺福韦后HBV复发发生率及相关因素

Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-29

研究纳入台湾135例无肝硬化慢性HBV感染患者(恩替卡韦79例、替诺福韦56例),治疗结束时HBsAg<100 IU/mL,随访中位87周;另108例为验证组,随访中位126周。5年病毒学复发率40.9%、临床复发率32.5%、HBsAg清除率47%。治疗结束时HBsAg<40 IU/mL者5年病毒学复发17.3%,≥40 IU/mL者为67.6%(P<.001)。

要点

  • 治疗结束时HBsAg<40 IU/mL者5年病毒学复发17.3%,≥40 IU/mL者为67.6%(P<.001)。
  • 验证组对应5年病毒学复发率分别为31.1%与80.5%(P<.001)。
  • 治疗结束时HBsAg<40 IU/mL且基线HBV DNA<5×10^4 IU/mL或基线HBcrAg<4 log U/mL者5年复发率<10%。

核心结论

  • 治疗结束时HBsAg≤40 IU/mL是停止核苷(酸)类似物治疗的最佳阈值。
  • 等待至基线HBV DNA 5×10^4 IU/mL或HBcrAg 4 log U/mL与治疗结束时HBsAg 40 IU/mL组合后再停药可能降低HBV复发风险。

研究设计与样本

  • 研究为多中心队列研究,开发组收集2007至2015年使用恩替卡韦或2011至2016年使用替诺福韦酯的台湾无肝硬化慢性HBV感染患者135例(恩替卡韦79例、替诺福韦56例),治疗结束时HBsAg<100 IU/mL,随访中位87周(四分位距48-161周)。
  • 验证组收集台湾其他医疗中心108例患者,随访中位126周(四分位距61-214周)。
  • 病毒学复发定义为血清HBV DNA>2000 IU/mL;临床复发定义为丙氨酸氨基转移酶>80 U/L且HBV DNA>2000 IU/mL。

主要发现

  • 开发组5年病毒学复发率、临床复发率和HBsAg清除率分别为40.9%、32.5%和47%。
  • 基线HBV DNA和治疗结束时HBsAg水平与复发独立相关。
  • 开发组治疗结束时HBsAg<40 IU/mL者5年病毒学复发17.3%,≥40 IU/mL者67.6%(P<.001);临床复发分别为10.2%和57.6%(P<.001)。
  • 验证组治疗结束时HBsAg<40 IU/mL与≥40 IU/mL者5年病毒学复发率分别为31.1%和80.5%(P<.001),临床复发率分别为14.2%和50.3%(P<.001)。
  • 开发组治疗结束时HBsAg<40 IU/mL且基线HBV DNA<5×10^4 IU/mL或基线HBcrAg<4 log U/mL者5年病毒学和临床复发率均<10%。

关键数值与推荐

  • 治疗结束时HBsAg<40 IU/mL者5年病毒学复发17.3%,≥40 IU/mL者67.6%(P<.001)(开发组)。
  • 治疗结束时HBsAg<40 IU/mL者5年临床复发10.2%,≥40 IU/mL者57.6%(P<.001)(开发组)。
  • 验证组治疗结束时HBsAg<40 IU/mL与≥40 IU/mL者5年病毒学复发率分别为31.1%和80.5%(P<.001)。
  • 验证组治疗结束时HBsAg<40 IU/mL与≥40 IU/mL者5年临床复发率分别为14.2%和50.3%(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We investigated the incidence and factors associated with relapse of hepatitis B virus (HBV) infection in patients with levels of HB surface antigen (HBsAg) less than 100 IU/mL after cessation of entecavir or tenofovir disoproxil fumarate (TDF) treatment. METHODS: We collected data from patients with chronic HBV infection without cirrhosis treated with entecavir from 2007 through 2015 or TDF from 2011 through 2016 in Taiwan. We identified 135 patients with levels of HBsAg less than 100 IU/mL at the end of treatment (79 entecavir and 56 TDF) and collected data from them for a median of 87 weeks (interquartile range, 48-161 wk) for use as the development set. We collected data from 108 patients from separate medical centers in Taiwan, followed up for a median of 126 weeks (interquartile range, 61-214 wk), and used these as the validation group. Post-treatment virologic relapse was defined as a serum HBV DNA level greater than 2000 IU/mL, and clinical relapse was defined as an alanine aminotransferase level greater than 80 U/L and a HBV DNA level greater than 2000 IU/mL. RESULTS: In the development group, the 5-year incidences of virologic relapse, clinical relapse, and HBsAg loss were 40.9%, 32.5%, and 47%, respectively. The baseline HBV DNA and end-of-treatment levels of HBsAg were associated independently with relapse. In the development group, 17.3% of patients with end-of-treatment HBsAg levels less than 40 IU/mL had a virologic relapse within 5 years, whereas 67.6% of patients with a HBsAg level of 40 IU/mL or more had a virologic relapse within 5 years (P < .001); proportions of patients with clinical relapses were 10.2% (HBsAg <40 IU/mL) and 57.6% (HBsAg ≥40 IU/mL; P < .001). In the validation groups, for patients with end-of-treatment HBsAg levels less than 40 IU/mL or 40 IU/mL or more, the rates of virologic relapse at 5 years were 31.1% and 80.5% (P < .001), and rates of clinical relapse were 14.2% and 50.3% (P < .001), respectively. Rates of virologic and clinical relapse within 5 years were low (<10%) in patients with a combination of end-of-treatment HBsAg level less than 40 IU/mL and baseline HBV DNA level less than 5 × 104 IU/mL, or baseline hepatitis B core-related antigen level less than 4 log U/mL in the development group. CONCLUSIONS: An end-of-treatment HBsAg level of 40 IU/mL or less is optimal for stopping nucleos(t)ide analog therapy. Waiting to stop therapy until patients have a combination of baseline HBV DNA level of 5 × 104 IU/mL or hepatitis B core-related antigen of 4 log U/mL and end-of-treatment HBsAg level of 40 IU/mL might reduce the risk of HBV relapse.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tseng TN, Hu TH, Wang JH, et al. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clin Gastroenterol Hepatol. 2020. PMID: 32360818. doi:10.1016/j.cgh.2020.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。